A Study of Abemaciclib in Indian Women With Advanced Breast Cancer

PHASE4CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

February 22, 2021

Primary Completion Date

January 9, 2023

Study Completion Date

January 9, 2023

Conditions
Breast NeoplasmsNeoplasm Metastasis
Interventions
DRUG

Abemaciclib

Administered orally

DRUG

Nonsteroidal Aromatase Inhibitor (NSAI)

Letrozole or anastrozole administered orally (physician choice)

DRUG

Fulvestrant

Administered intramuscularly

Trial Locations (15)

110085

Rajiv Gandhi Cancer Institute And Research Centre, New Delhi

160055

Max Superspeciality Hospital, Chandigarh

391760

Kailash Cancer Hospital & Research Centre (KCHRC), Waghodia

395002

Nirmal Hospital Pvt Ltd., Surat

Unique Hospital Multispecialty & Research Institute, Surat

411001

Ruby Hall Clinic and Grant Medical Foundation, Pune

422001

HCG Manavata Cancer Centre, Nashik

440001

Kingsway Hospital, Nagpur

440012

Meditrina Institute of Medical Sciences, Nagpur

452001

SRJ-CBCC Cancer Hospital, Indore

500004

MNJ Institute of Oncology, Hyderabad

560020

HCG Cancer Centre, Kalinga Rao Road, Bengaluru

695011

Regional Cancer Centre, Trivandrum

700054

Apollo Gleneagles Hospitals Kolkata, Kolkata

800014

Indira Gandhi Institute of Medical Sciences, Patna

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04707196 - A Study of Abemaciclib in Indian Women With Advanced Breast Cancer | Biotech Hunter | Biotech Hunter